Christine Elsholz, MD
Family Medicine · Bridgeport, MINPI 1073595674
Payments from drug & device makers
Across 76 payments — averaging $15.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$220
- Pfizer$165
- Lilly USA, LLC$128
- GSK$109
- Astellas Pharma US Inc$70
- Novo Nordisk$66
- plus $451 from 16 others
What the payments were for
- Food & beverage$1,19699%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 15 | $220 |
| Pfizer | 11 | $165 |
| Lilly USA, LLC | 9 | $128 |
| GSK | 8 | $109 |
| Astellas Pharma US Inc | 4 | $70 |
| Novo Nordisk | 4 | $66 |
| Exact Sciences | 2 | $49 |
| Boehringer Ingelheim | 3 | $48 |
| Dexcom, Inc. | 3 | $45 |
| Xeris Pharmaceuticals, Inc. | 2 | $41 |
| Biohaven Pharmaceuticals, Inc. | 1 | $38 |
| AstraZeneca | 2 | $30 |
| Sanofi-aventis U.S. LLC | 2 | $30 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $27 |
| Johnson & Johnson | 1 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Circassia Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Medtronic | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $12 |
How this compares
$1,210 in reported general payments places this provider in the 70th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 71 | $63,250 |
| TrulicityDulaglutide | 45 | $52,104 |
| OzempicSemaglutide | 51 | $48,749 |
| JardianceEmpagliflozin | 33 | $46,406 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 54 | $37,533 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 13 | $28,996 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 20 | $19,819 |
| MounjaroTirzepatide | 15 | $19,695 |
| OxycontinOxycodone Hcl | 24 | $14,825 |
| Incruse ElliptaUmeclidinium Bromide | 40 | $13,682 |
| JanuviaSitagliptin Phosphate | 17 | $13,113 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $12,226 |
| EliquisApixaban | 12 | $11,294 |
| Spiriva RespimatTiotropium Bromide | 12 | $8,998 |
| MyrbetriqMirabegron | 17 | $8,195 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $30 | $79,661108 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $128 | $71,79960 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta, Shingrix | $109 | $59,133122 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $48 | $55,40445 claims |
| Novo NordiskOzempic | $66 | $48,74951 claims |
| PfizerEliquis | $165 | $11,29412 claims |
| Astellas Pharma US IncMyrbetriq | $70 | $8,19517 claims |
| Sanofi-aventis U.S. LLCLantus | $30 | $2,51421 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Bridgeport
- Derrick WilliamsonSouthfield$9.9M
- Rebecca RivardRoseville$7M
- Paul BensonBerkley$4.2M
- Michael HafranEast Lansing$2.7M
- Mitzie HewittBuckley$1.3M
- Loren ChudlerSouthfield$1.3M
- Solomon AmsterWhite Lake$981K
- Matt RosenbergJackson$559K
- Rhonda MejeurGrand Rapids$493K
- Steve LasaterSaint Johns$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.